clinicallaser.seCrawled Nov 19, 2026
CLS Americas partnered with Genesis Research to conduct a Phase I clinical study on laser ablation for prostate cancer.
CLS explains how its FDA-cleared laser ablation system for neurosurgery works.
CLS began with pipeline research and now conducts clinical studies to develop new therapies for serious diseases, including cancer.
CLS develops and commercializes minimally invasive therapy systems that use heat from focused laser light for image-guided tissue ablation.
Combined products enable minimally-invasive, high precision laser focal therapy of prostate tumors in an office or clinic. CLS Americas and Focalyx Technologies, today announced the companies will exhibit and demonstrate their respective products.
CLS’s CTO Cristina Pantaleone and VP Medical Affairs Hoda Tawfik discuss the design of TRANBERG Thermal Therapy Systems for precise and safe focal therapy of soft tissue, such as the prostate gland, and outline current research efforts.
CLS and Skåne University Hospital will evaluate laser ablation for glioblastoma patients in a clinical trial.
CLS has entered an agreement with Quadia Diagnostic Imaging Center in Piaseczno, Poland on a commercial evaluation of its second-generation TRANBERG Thermal Therapy System with Thermoguide Workstation in MR-guided stereotactic focal laser ablation of localized prostate cancer.
CLS participated in the 2022 European Conference on Interventional Oncology in Vienna, Austria.
Radboud University Medical Center approved a trial to evaluate magnetic resonance-guided laser ablation for localized prostate cancer using the TRANBERG Thermal Therapy System.
SVT’s local news featured Skåne University Hospital’s use of CLS systems for brain tumor operations inside an MRI.
CLS seeks candidates to join its team focused on precise cancer treatment.
Joel Hix, Director of Clinical Operations at CLS Americas, has over 15 years of senior management experience in operations, sales, marketing, and service for medical device manufacturers including Boston Scientific and Healthtronics.
CLS’s board has experience in the medtech industry, commercialization of medtech products, oncology, and financial markets. Peter Max, born in 1961, has served as Chairman of the Board since 2024.
CLS’s management team has experience in product and business development for medtech products, cancer care, regulatory work, and international marketing. Dan J. Mogren has served as CEO since 2022.
CLS develops precise treatment tools for laser ablation of diseased tissue.
Professor Karl-Göran Tranberg’s research into laser-generated thermal ablation of cancer tumors revealed the immune system’s ability to target cancer cells throughout the body, known as the abscopal effect.
CLS’s journey began in 2006 with Professor Karl-Göran Tranberg’s discovery that laser beams could destroy cancer and activate the immune system. In 2023, the ClearPoint Prism Neuro Laser Therapy System launched for minimally invasive brain surgery.
CLS has offices in Europe, North America, and Asia, with its head office in Lund, Sweden.
CLS provides tools for precise tissue ablation using laser-generated heat, targeting advancements in cancer care and neurosurgery.
Clinical Laserthermia Systems AB is a public company based in Skåne County, Lund, developing, manufacturing, importing, and trading medical equipment.
Villkor för teckningsoptioner TO 5_Terms for warrants of series TO 5 (SE_ENG)
CLS promotes Jimmy Johansson to Executive VP Operations, a new role aimed at optimizing the company’s operations and supporting its growth. Johansson, who joined in 2015, previously led the development of the Thermoguide™ Workstation, a tool for MRI-guided laser ablation. The company also collaborates with ClearPoint Neuro at the CNS 2024 conference in Houston, highlighting advancements in neuro-interventional technologies.
CLS secures two abstracts for presentation at the **15th FTS Annual Meeting**, highlighting advancements in its **TRANBERG system**. The company also promotes **Jimmy Johansson**, Executive VP Operations since May, to a newly created role aimed at optimizing operations and supporting growth. Johansson previously led the development of **Thermoguide™ Workstation**, a tool for MRI-guided laser ablation monitoring.
CLS organizes a training camp in Turin, Italy, to advance expertise in medical device applications. The company leverages Jimmy Johansson’s experience in healthcare sectors, including his role as project manager for the **Thermoguide™ Workstation**, a tool for MRI-guided laser ablation monitoring. Johansson was recently appointed **Executive VP Operations** to optimize CLS’s operational efficiency and support its growth.
Jimmy Johansson, a veteran in medical devices and healthcare, leads CLS’s newly created Executive VP Operations role to optimize workflows and support growth. He previously managed development of the Thermoguide™ Workstation, a tool for MRI-guided laser ablation monitoring. The position consolidates operational oversight across the company’s medical technology initiatives.
CLS participates in the Imperial Prostate Masterclass in London, showcasing advancements in prostate cancer treatment. The company highlights its Thermoguide™ Workstation, a tool for monitoring MRI-guided laser ablation procedures. Jimmy Johansson, CLS’s Executive VP Operations since May, leads operational coordination to support the company’s growth in medical device innovation.
Jimmy Johansson, a veteran of the medical device and healthcare sectors, now leads CLS as Executive VP Operations. He oversees a newly created role to streamline operations and support the company’s growth, following his prior work on the Thermoguide™ Workstation—a tool for MRI-guided laser ablation monitoring. Johansson has contributed to CLS since 2015, including project management for key product development.
CLS participated in the **Focal Therapy Masterclass** in Paris, hosted by the **European Association of Urology (EAU)**. The event brought together **key opinion leaders (KOLs)** in focal therapy alongside urologists new to the field but eager to adopt it. CLS engaged with both **leading experts** and **clinicians preparing to implement focal therapy** in their practices.